Table 1 In vivo immunosuppressive... | American Society of Hematology

Table 1

In vivo immunosuppressive effects of MSCs

Animal, model	MSCs	Outcome	Reference no.
Mouse			36
Melanoma	Allogeneic IV and SC infusion	Promotion of tumor growth	—
GVHD	Allogeneic multiple IV infusions	Prevention of GVHD	62
GVHD	Allogeneic single IV infusion	No effect on development of GVHD	63
Graft rejection	Syngeneic	Decreased graft rejection	61
EAE	Allogeneic IV infusion	Prevention of EAE development	47
CIA	Allogeneic IV infusion	No effect	65
Baboon: Skin graft transplantation	Allogeneic IV infusion	Prolonged skin graft survival	35
Rat: Ischemia/reperfusion injury	Allogeneic IV infusion	Protection against renal ischemia/reperfusion injury	66
Human
Acute myeloid leukemia	Haploidentical IV infusion	HSC engraftment with no GVHD	91
Severe acute GVHD	Haploidentical IV infusion	Resolution of grade IV acute GVHD	71, 73
Leukemia	Haploidentical IV infusion	Rapid platelet engraftment, low incidence of GVHD	70

Animal, model	MSCs	Outcome	Reference no.
Mouse			36
Melanoma	Allogeneic IV and SC infusion	Promotion of tumor growth	—
GVHD	Allogeneic multiple IV infusions	Prevention of GVHD	62
GVHD	Allogeneic single IV infusion	No effect on development of GVHD	63
Graft rejection	Syngeneic	Decreased graft rejection	61
EAE	Allogeneic IV infusion	Prevention of EAE development	47
CIA	Allogeneic IV infusion	No effect	65
Baboon: Skin graft transplantation	Allogeneic IV infusion	Prolonged skin graft survival	35
Rat: Ischemia/reperfusion injury	Allogeneic IV infusion	Protection against renal ischemia/reperfusion injury	66
Human
Acute myeloid leukemia	Haploidentical IV infusion	HSC engraftment with no GVHD	91
Severe acute GVHD	Haploidentical IV infusion	Resolution of grade IV acute GVHD	71, 73
Leukemia	Haploidentical IV infusion	Rapid platelet engraftment, low incidence of GVHD	70

EAE indicates experimental acute encephalomyelitis; IV, intravenous; SC, subcutaneous; and —, not applicable.